ORTX

Orchard Therapeutics Plc

A biotechnology company that makes one-time gene therapies for rare, often fatal genetic diseases. Its approach takes a patient's own blood stem cells, fixes a faulty gene outside the body, and returns the corrected cells to the patient. Its flagship treatment, Libmeldy (Lenmeldy in the US), targets metachromatic leukodystrophy, a rare nerve-destroying disorder — the name echoes the disease's initials. Founded in 2015 by gene-therapy pioneers, the company was acquired by Japanese drugmaker Kyowa Kirin in 2024.

Orchard Therapeutics plc ADR

Recent Activity

Show $

2020Q3

2 sells

ArrowMark PartnersEXIT

-440.8K shares

ArrowMark PartnersEXIT

-440.8K shares

Meridian Contrarian FundEXIT

-95.6K shares

Meridian Contrarian FundEXIT

-95.6K shares

2020Q2

2 sells

ArrowMark PartnersTRIM

-1.05M shares(-70.4%)

ArrowMark PartnersTRIM

-1.05M shares(-70.4%)

Meridian Contrarian FundTRIM

-104.4K shares(-52.2%)

Meridian Contrarian FundTRIM

-104.4K shares(-52.2%)

2020Q1

2 buys

ArrowMark PartnersADD

+179.7K shares(+13.7%)

ArrowMark PartnersADD

+179.7K shares(+13.7%)

Meridian Contrarian FundADD

+80.0K shares(+66.7%)

Meridian Contrarian FundADD

+80.0K shares(+66.7%)

Loading more activity...